RxDoctor Payments DataLook up a doctor →

Paul Eber, MD

Urology · Germantown, TNNPI 1124085634

Payments from drug & device makers

$795,093in general payments, 2019–2025

Across 979 payments — averaging $812.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dendreon Pharmaceuticals LLC$227K
  • Astellas Pharma US Inc$118K
  • Sumitomo Pharma America, Inc.$115K
  • Janssen Research & Development, LLC$102K
  • Bayer$94K
  • Johnson & Johnson$69K
  • plus $70K from 51 others

What the payments were for

  • Consulting fees$36,1438%
  • Speaking & faculty fees$365,29577%
  • Travel & lodging$56,41712%
  • Food & beverage$17,8574%
  • Education$3520%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$795,093 in reported general payments places this provider in the 95th percentile of 276 urology providers in Tennessee.

See all urology providers in Tennessee

Medicare billing

Part B allowed, 2024
$2,491,411
Medicare patients
1,398
Services billed
71,074

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide436$6,118,159
NubeqaDarolutamide203$2,705,893
XtandiEnzalutamide149$2,068,157
OrgovyxRelugolix727$1,932,516
LynparzaOlaparib15$284,058
Abiraterone Acetate131$166,265
YonsaAbiraterone Acet,submicronized14$143,872
ZytigaAbiraterone Acetate11$123,100
GemtesaVibegron73$60,036
MyrbetriqMirabegron83$59,591
Tamsulosin Hcl662$12,559
Solifenacin Succinate105$8,880
Dutasteride162$5,446
Silodosin70$4,055
Potassium Citrate ErPotassium Citrate16$2,613

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada, Zytiga$68,651$6,241,258447 claims
BayerNubeqa$94,359$2,705,893203 claims
Astellas Pharma US IncXtandi, Myrbetriq$117,616$2,127,748232 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$115,405$1,992,552800 claims
AstraZenecaLynparza$19,135$284,05815 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$2,074$166,265131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 276 urology providers in Tennessee.

Other urology in Germantown

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →